Online inquiry

IVTScrip™ mRNA-Anti-CD79B, MCDS0593A(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10991MR)

This product GTTS-WQ10991MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD79B gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000626.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 974
UniProt ID P40259
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD79B, MCDS0593A(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ10991MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10625MR IVTScrip™ mRNA-Anti-MAPT, LY-3303560(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA LY-3303560
GTTS-WQ14951MR IVTScrip™ mRNA-Anti-PDCD1, SHR-1210(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA SHR-1210
GTTS-WQ3900MR IVTScrip™ mRNA-Anti-CD274, BCD-135(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BCD-135
GTTS-WQ7763MR IVTScrip™ mRNA-Anti-MMP9, GS-5745(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GS-5745
GTTS-WQ5993MR IVTScrip™ mRNA-Anti-ITGAV&ITGB3, CNTO 095(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA CNTO 095
GTTS-WQ3640MR IVTScrip™ mRNA-Anti-FGFR2, BAY 1187982(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BAY 1187982
GTTS-WQ8454MR IVTScrip™ mRNA-Anti-TLR3 Agonist, HspE7(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA HspE7
GTTS-WQ2750MR IVTScrip™ mRNA-Anti-TNFSF11, AMG162(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AMG162
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW